Methamphetamine use has become an increasingly important public health issue, particularly in the United States. This powerful stimulant affects the central nervous system and is linked to serious cardiovascular complications, including acute coronary syndrome (ACS), which includes heart attacks and unstable angina.
A new retrospective cohort study published in the Journal of the American Heart Association provides one of the most detailed examinations to date of methamphetamine-associated ACS. The findings highlight not only clinical risks but also significant social and healthcare disparities affecting outcomes.
The study, conducted at Santa Clara Valley HealthCare in California, reviewed patient records from 2012 to 2022. It included 1,309 adults aged 18 to 65 who were diagnosed with ACS and underwent coronary angiography.
Among them:
Researchers focused on mortality outcomes, coronary artery findings, and long-term cardiovascular risk.
This is currently one of the largest single-center studies examining methamphetamine use in ACS patients.
One of the most important findings is that methamphetamine use was strongly associated with worse survival outcomes.
Even after adjusting for factors like age, diabetes, kidney function, and heart function, methamphetamine use remained the strongest independent predictor of death. The adjusted hazard ratio was 2.08, meaning patients with methamphetamine use had more than double the risk of death compared to non-users.
This finding is critical because many methamphetamine users were younger and had fewer traditional cardiovascular risk factors.
Patients with methamphetamine-associated ACS were typically:
However, they had:
This combination of biological and social risk factors appears to contribute heavily to poor outcomes.
A major clinical finding was the difference in coronary artery disease patterns.
Patients with methamphetamine use were more likely to have nonobstructive coronary disease (24.2% vs 10.6%). This condition, often called myocardial infarction with nonobstructive coronary arteries (MINOCA), can be caused by:
Because there is often no major blockage, these patients were less likely to receive procedures like stents or bypass surgery.
Even though these patients experienced serious cardiac events, they were less likely to receive standard post-heart attack treatments.
Compared with non-methamphetamine patients, they were less likely to be discharged on:
This underuse of guideline-based therapies may contribute to higher recurrence rates and mortality.
The study also found that methamphetamine users had significantly higher rates of repeat hospital admissions for ACS:
This suggests that even after initial treatment, these patients remain at high risk of further cardiac events.
Long-term survival analysis showed consistently worse outcomes in methamphetamine users across multiple follow-up periods.
A key feature of this research is the emphasis on social determinants of health.
Patients with methamphetamine-associated ACS had:
These findings suggest that health outcomes are not driven solely by biology, but also by housing stability, substance use patterns, and access to care.
Methamphetamine affects the cardiovascular system in multiple ways:
Unlike traditional heart disease, methamphetamine-related ACS can occur even in people without significant plaque buildup.
The study also notes differences between methamphetamine and other stimulants like cocaine.
Methamphetamine has a longer half-life and may produce more prolonged cardiovascular stress. This may partly explain why outcomes appear worse in methamphetamine-associated ACS compared to other drug-related heart conditions.
The findings suggest several important changes in clinical practice:
Doctors should consider routine screening for substance use in younger ACS patients.
Patients may benefit from combined cardiology and addiction medicine treatment.
Even in nonobstructive disease, patients still require medications like statins and antiplatelets when appropriate.
Addressing homelessness, substance use, and healthcare access is likely critical for improving survival.
Methamphetamine use is increasing in many regions, making these findings especially concerning. The study suggests that methamphetamine-associated ACS may be underrecognized and underdiagnosed, particularly in emergency settings where toxicology screening is not always performed.
Without intervention, the burden on healthcare systems may continue to rise.
While this is one of the largest studies of its kind, it has limitations:
Despite these limitations, the findings were consistent across multiple analyses.
This large cohort study published in the Journal of the American Heart Association demonstrates a clear association between methamphetamine use and worse outcomes in acute coronary syndrome.
Even though patients were younger and had fewer traditional risk factors, they experienced:
Methamphetamine use emerged as a powerful independent predictor of death, highlighting the urgent need for targeted prevention strategies, improved screening, and integrated addiction and cardiovascular care.
Zhao SX, Xu W, Jaradeh M, et al. Methamphetamine Use Among Adult Patients Presenting With Acute Coronary Syndrome: A Single-Center Retrospective Cohort Study. Journal of the American Heart Association. 2026.
This article is a rewritten educational summary based on a peer-reviewed research study. It is intended for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider for medical concerns or before making decisions related to health conditions or substance use.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.